The Effect of Bovine Basic Fibroblast Growth Factor on Skin Flap Survival in Rats

Im, Michael J.; Kim, Young S.; Edwards, Richard; Hoopes, John E.; Fenselau, Allan

doi:10.1097/00000637-199203000-00007

Cited by 33 publications

(24 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Employing a similar skin flap model, several groups have reported results comparable to this study by injecting recombinant FGF-2 either into or under the flap at the time of surgery. 34,[43][44][45] Each of these cases employed high single doses of FGF-2, ranging from 1 to 20 g, in comparison to the daily regimens of 2.6 ng employed in this study. The success of FGF-2 in models of acute ischemia is likely to be due to its multipotency, which enables it to induce the proliferation of a variety of cell types, including fibroblasts, endothelial cells and smooth muscle cells.…”

Section: Figure 7 Histology At Day 7 After Implantation Showing the Imentioning

confidence: 99%

Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia

et al. 2001

View full text Add to dashboard Cite

Stimulating angiogenesis by gene transfer approaches offers the hope of treating tissue ischemia which is untreatable by currently practiced techniques of vessel grafting and bypass surgery. Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (FGF-2) are potent angiogenic molecules, making them ideal candidates for novel gene transfer protocols designed to promote new blood vessel growth. In this study, an ex vivo gene therapy approach utilizing cell encapsulation was employed to deliver VEGF and FGF-2 in a continuous and localized manner. C(2)C(12) myoblasts were genetically engineered to secrete VEGF(121), VEGF(165) and FGF-2. These cell lines were encapsulated in hollow microporous polymer membranes for transplantation in vivo. Therapeutic efficacy was evaluated in a model of acute skin flap ischemia. Capsules were positioned under the distal, ischemic region of the flap. Control flaps showed 50% necrosis at 1 week. Capsules releasing either form of VEGF had no effect on flap survival, but induced a modest increase in distal vascular supply. Delivery of FGF-2 significantly improved flap survival, reducing necrosis to 34.2% (P < 0.001). Flap vascularization was significantly increased by FGF-2 (P < 0.01), with numerous vessels, many of which had a large lumen diameter, growing in the proximity of the implanted capsules. These results demonstrate that FGF-2, delivered from encapsulated cells, is more efficacious than either VEGF(121) or VEGF(165) in treating acute skin ischemia and improving skin flap survival. Furthermore, these data attest to the applicability of cell encapsulation for the delivery of angiogenic factors for the treatment and prevention of tissue ischemia

show abstract

Section: Figure 7 Histology At Day 7 After Implantation Showing the Imentioning

confidence: 99%

Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia

et al. 2001

View full text Add to dashboard Cite

show abstract

“…3 Without adequate tissue oxygen levels, wounds are more susceptible to infection, collagen production and fibroblast function is reduced, angiogenesis is hindered, and reepithelialization of the wound sur-face is impaired. 8 " 13 The objectives of this study were 1) to quantify tissue oxygen levels in nonirradiated and irradiated skin flaps treated with supplemental basic FGF (bFGF), 2) to compare skin flap vascularity in nonirradiated and irradiated skin flaps treated with supplemental bFGF, and 3) to characterize the epidermal regenerative effects of bFGF in skin flaps in nonirradiated and irradiated conditions. 7 Fibroblast growth factors (FGFs) have shown promise in increasing vascularity in wounds and incisional wound strength in ischémie and nonischemic animal models.…”

Section: Introductionmentioning

confidence: 99%

Vascular and Epidermal Effects of Fibroblast Growth Factor on Irradiated and Nonirradiated Skin Flaps

Hom

Simplot

Manivel

et al. 2000

Ann Otol Rhinol Laryngol

View full text Add to dashboard Cite

Head and neck cancer surgeons are often faced with the challenge of managing previously irradiated soft tissue that has poor vascularity and slower epithelialization. This study investigates the effect of supplemental basic fibroblast growth factor (bFGF) on flap vascularity, tissue oxygenation, and epidermal regeneration in nonirradiated (n = 40) and irradiated porcine skin flaps (n = 40). Supplemental bFGF increased vascularity in nonirradiated flaps by 80% (p = .005), with a trend to a higher tissue oxygen level by day 14. The irradiated bFGF-treated flaps did not show increased vascularity or higher tissue oxygen levels 2 weeks after surgery. However, in both irradiated and nonirradiated groups, epidermal regeneration increased by greater than 70% with supplemental bFGF (p < .002). The results of this study suggest that supplemental bFGF can increase tissue vascularity in nonirradiated tissues and epidermal regeneration in both nonirradiated and irradiated conditions.

show abstract

“…Several previous studies have shown that delivery of angiogenic growth factor to the skin flap significantly improved flap perfusion and viability. 1,3,27 However, the induction of angiogenic reactions in the recipient bed might also support improvement of flap perfusion by different mechanisms. This is because neovascular augmentation in the recipient bed potentially promotes the development of vascular channels between the flap and the recipient bed.…”

Section: Discussionmentioning

confidence: 99%

Controlled delivery of bFGF to recipient bed enhances the vascularization and viability of an ischemic skin flap

Fujihara

Koyama

Ohba

et al. 2008

Wound Repair Regeneration

View full text Add to dashboard Cite

Therapeutic angiogenesis is a promising approach to treat ischemic skin flaps. We delivered basic fibroblast growth factor (bFGF) to the recipient bed of a rat dorsal skin flap by a drug delivery system with acidic gelatin hydrogel microspheres (AGHMs), and assessed augmentation of neovascularization and flap viability. An axial skin flap was elevated on the back of male Sprague-Dawley rats, and bFGF solution or bFGF-impregnated AGHMs were injected into the recipient bed. The dose of bFGF in the bFGF solution was set to 15 (Sol-15 group), 50 (Sol-50 group), or 150 mug (Sol-150 group). Correspondingly, 2 mg AGHMs were impregnated with 15 (AGHM-15 group), 50 (AGHM-50 group), or 150 mug (AGHM-150 group) bFGF. Other groups of animals received phosphate-buffered saline (Sol-Cont group) or phosphate-buffered saline-impregnated AGHMs (AGHM-Cont group) as controls. Seven days later, analyses of the area of necrosis, microangiographic findings, and histological findings in the flap were carried out. The area of necrosis in the AGHM-150 group was significantly smaller than that in the other groups. Microangiographic and histological analyses showed that neovascularization of the ischemic skin flap significantly increased in the AGHM-150 group as compared with the Sol-150 group and the AGHM-Cont group. These findings suggest that continuous delivery of bFGF to the recipient bed by bFGF-impregnated AGHMs enhances the viability of an ischemic skin flap.

show abstract

The Effect of Bovine Basic Fibroblast Growth Factor on Skin Flap Survival in Rats

Cited by 33 publications

References 0 publications

Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia

Delivery of FGF-2 but not VEGF by encapsulated genetically engineered myoblasts improves survival and vascularization in a model of acute skin flap ischemia

Vascular and Epidermal Effects of Fibroblast Growth Factor on Irradiated and Nonirradiated Skin Flaps

Controlled delivery of bFGF to recipient bed enhances the vascularization and viability of an ischemic skin flap

Contact Info

Product

Resources

About